Akebia Therapeutics (AKBA) Intangibles (2018 - 2024)
Akebia Therapeutics (AKBA) posted quarterly Intangibles of $9.0 million for Q3 2024, down 80.0% year-over-year from $45.1 million in Q4 2023, and down 50.0% quarter-over-quarter from $18.0 million in Q2 2024.
Akebia Therapeutics (AKBA) Intangibles (2018 - 2024) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Intangibles for 7 consecutive years, with $9.0 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Intangibles fell 80.0% year-over-year to $9.0 million; the TTM figure through Sep 2024 stood at $9.0 million (down 80.0% YoY), while the FY2023 annual figure was $36.0 million, down 50.0% from the prior year.
- Intangibles eased to $9.0 million in Q3 2024 per AKBA's latest filing, from $18.0 million in the prior quarter.
- Across five years, Intangibles topped out at $282.1 million in Q1 2020 and bottomed at $9.0 million in Q3 2024.
- Historically, Intangibles has averaged $95.6 million across 5 years, with a median of $90.1 million in 2022.
- Annual changes were most pronounced in 2020 — Intangibles declined 11.43% — and 2024, when it slumped 80.0%.
- Akebia Therapeutics' Intangibles stood at $144.2 million in 2020, then dropped by 25.0% to $108.1 million in 2021, then slumped by 33.33% to $72.1 million in 2022, then slumped by 50.0% to $36.0 million in 2023, then sank by 75.0% to $9.0 million in 2024.
- Business Quant data shows AKBA's Intangibles at $9.0 million in Q3 2024, $18.0 million in Q2 2024, and $27.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 918.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 21.28 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 13.68 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 2.23 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.20 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.12 Bn |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 9.01 Mn |
| Jun 30, 2024 | 18.02 Mn |
| Mar 31, 2024 | 27.03 Mn |
| Dec 31, 2023 | 36.04 Mn |
| Sep 30, 2023 | 45.05 Mn |
| Jun 30, 2023 | 54.06 Mn |
| Mar 31, 2023 | 63.07 Mn |
| Dec 31, 2022 | 72.08 Mn |
| Sep 30, 2022 | 81.10 Mn |
| Jun 30, 2022 | 90.11 Mn |
| Mar 31, 2022 | 99.12 Mn |
| Dec 31, 2021 | 108.13 Mn |
| Sep 30, 2021 | 117.14 Mn |
| Jun 30, 2021 | 126.15 Mn |
| Mar 31, 2021 | 135.16 Mn |
| Dec 31, 2020 | 144.17 Mn |
| Sep 30, 2020 | 151.38 Mn |
| Jun 30, 2020 | 157.48 Mn |
| Mar 31, 2020 | 282.11 Mn |
| Dec 31, 2019 | 291.21 Mn |